Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy.

Korean journal of ophthalmology : KJO

Volumn 26, Issue 2, 2012, Pages 139-142

  Entezari, Morteza ^a   Ramezani, Alireza ^b   Yaseri, Mehdi ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CENTRAL SEROUS RETINOPATHY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; TREATMENT OUTCOME; VISUAL ACUITY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CENTRAL SEROUS CHORIORETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84864875693     PISSN: 10118942     EISSN: None     Source Type: Journal    
DOI: 10.3341/kjo.2012.26.2.139     Document Type: Article

References (0)